RU2013114246A - Комбинация hdac ингибиторов с лекарственными средствами против тромбоцитопении - Google Patents
Комбинация hdac ингибиторов с лекарственными средствами против тромбоцитопении Download PDFInfo
- Publication number
- RU2013114246A RU2013114246A RU2013114246/15A RU2013114246A RU2013114246A RU 2013114246 A RU2013114246 A RU 2013114246A RU 2013114246/15 A RU2013114246/15 A RU 2013114246/15A RU 2013114246 A RU2013114246 A RU 2013114246A RU 2013114246 A RU2013114246 A RU 2013114246A
- Authority
- RU
- Russia
- Prior art keywords
- combination
- drug
- thrombocytopenia
- group
- use according
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/15—Depsipeptides; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/196—Thrombopoietin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
1. Применение комбинации (а) N-гидрокси-3-[4-[[[2-(2-метил-1H-индол-3-ил)этил]амино]метил]фенил]-2Е-2-пропенамида или его фармацевтически приемлемой соли в комбинации с (b) лекарственным препаратом против тромбоцитопении для получения лекарственного средства, предназначенного для лечения множественной миеломы.2. Применение по п.1, где лекарственным средством против тромбоцитопении является ТПО-миметик.3. Применение по п.2, где лекарственным средством против тромбоцитопении является элтромбопаг, ромиплостим или их сочетание.4. Применение по п.3, где комбинация дополнительно включает дополнительное лекарственное средство, эффективное для лечения множественной миеломы.5. Применение по п.4, где лекарственным средством является протеосомный ингибитор.6. Применение по п.5, где протеосомным ингибитором является бортезомиб.7. Применение по п.6, где комбинация дополнительно включает дексаметазон.8. Применение комбинации, содержащей(a) HDACi ингибитор, выбранный из группы, состоящей из панобиностата, ромидепсина, вориностата и их сочетаний;(b) лекарственное средство против ТЦП, выбранное из группы, состоящей из элтромбопага, ромиплостима или их сочетания; и необязательно(c) анти-метаболит, выбранный из группы, состоящей из 5-азацитидина, децитабина или их сочетания;для получения лекарственного средства, предназначенного для лечения МДС и/или ОМЛ.
Claims (8)
1. Применение комбинации (а) N-гидрокси-3-[4-[[[2-(2-метил-1H-индол-3-ил)этил]амино]метил]фенил]-2Е-2-пропенамида или его фармацевтически приемлемой соли в комбинации с (b) лекарственным препаратом против тромбоцитопении для получения лекарственного средства, предназначенного для лечения множественной миеломы.
2. Применение по п.1, где лекарственным средством против тромбоцитопении является ТПО-миметик.
3. Применение по п.2, где лекарственным средством против тромбоцитопении является элтромбопаг, ромиплостим или их сочетание.
4. Применение по п.3, где комбинация дополнительно включает дополнительное лекарственное средство, эффективное для лечения множественной миеломы.
5. Применение по п.4, где лекарственным средством является протеосомный ингибитор.
6. Применение по п.5, где протеосомным ингибитором является бортезомиб.
7. Применение по п.6, где комбинация дополнительно включает дексаметазон.
8. Применение комбинации, содержащей
(a) HDACi ингибитор, выбранный из группы, состоящей из панобиностата, ромидепсина, вориностата и их сочетаний;
(b) лекарственное средство против ТЦП, выбранное из группы, состоящей из элтромбопага, ромиплостима или их сочетания; и необязательно
(c) анти-метаболит, выбранный из группы, состоящей из 5-азацитидина, децитабина или их сочетания;
для получения лекарственного средства, предназначенного для лечения МДС и/или ОМЛ.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37923810P | 2010-09-01 | 2010-09-01 | |
| US61/379,238 | 2010-09-01 | ||
| PCT/US2011/049842 WO2012030886A1 (en) | 2010-09-01 | 2011-08-31 | Combination of hdac inhibitors with thrombocytopenia drugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2013114246A true RU2013114246A (ru) | 2014-10-20 |
Family
ID=44645808
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013114246/15A RU2013114246A (ru) | 2010-09-01 | 2011-08-31 | Комбинация hdac ингибиторов с лекарственными средствами против тромбоцитопении |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20130171141A1 (ru) |
| EP (1) | EP2611436A1 (ru) |
| JP (2) | JP2013538810A (ru) |
| KR (1) | KR20130101519A (ru) |
| CN (2) | CN103079551A (ru) |
| AU (1) | AU2011296047A1 (ru) |
| BR (1) | BR112013004714A2 (ru) |
| CA (1) | CA2808908A1 (ru) |
| MX (1) | MX2013002503A (ru) |
| RU (1) | RU2013114246A (ru) |
| WO (1) | WO2012030886A1 (ru) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6551963B2 (ja) * | 2014-05-14 | 2019-07-31 | 国立大学法人京都大学 | 巨核球前駆細胞の製造方法 |
| US10702517B2 (en) * | 2015-04-22 | 2020-07-07 | Celgene Quanticel Research, Inc. | Bromodomain inhibitor |
| EP3534965A4 (en) * | 2016-11-03 | 2020-06-24 | Trillium Therapeutics Inc. | IMPROVEMENTS IN CD47 BLOCKADERAPY THROUGH HDAC INHIBITORS |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CY2010012I2 (el) | 2000-05-25 | 2020-05-29 | Novartis Ag | Μιμητικα θρομβοποιητινης |
| US20080221126A1 (en) * | 2005-08-03 | 2008-09-11 | Atadja Peter W | Use of Hdac Inhibitors for the Treatment of Myeloma |
| EP1954284A4 (en) * | 2005-11-04 | 2010-01-06 | Merck & Co Inc | ANTICANCER TREATMENT OF SAHA AND PEMETREXED |
| RU2469717C2 (ru) * | 2006-12-04 | 2012-12-20 | Новартис Аг | Комбинация ингибитора гда и антиметаболита |
| RU2009134223A (ru) * | 2007-02-15 | 2011-03-20 | Новартис АГ (CH) | Комбинация lbh589 с другими терапевтическими средствами, предназначенная для лечения рака |
| UY30915A1 (es) * | 2007-02-16 | 2008-09-02 | Smithkline Beecham Corp | Método de tratamiento de canceres |
| WO2010009285A1 (en) * | 2008-07-18 | 2010-01-21 | Novartis Ag | Use of hdac inhibitors for the treatment of acute myeloid leukemia and/or myelodysplastic syndrome |
| US20100152100A1 (en) * | 2008-07-30 | 2010-06-17 | Gloucester Pharmaceuticals, Inc. | Accelerated therapy |
-
2011
- 2011-08-31 US US13/819,735 patent/US20130171141A1/en not_active Abandoned
- 2011-08-31 RU RU2013114246/15A patent/RU2013114246A/ru not_active Application Discontinuation
- 2011-08-31 MX MX2013002503A patent/MX2013002503A/es not_active Application Discontinuation
- 2011-08-31 CA CA2808908A patent/CA2808908A1/en not_active Abandoned
- 2011-08-31 AU AU2011296047A patent/AU2011296047A1/en not_active Abandoned
- 2011-08-31 CN CN2011800424183A patent/CN103079551A/zh active Pending
- 2011-08-31 CN CN201410719941.0A patent/CN104399081A/zh active Pending
- 2011-08-31 WO PCT/US2011/049842 patent/WO2012030886A1/en active Application Filing
- 2011-08-31 JP JP2013527242A patent/JP2013538810A/ja active Pending
- 2011-08-31 KR KR1020137008049A patent/KR20130101519A/ko not_active Application Discontinuation
- 2011-08-31 BR BR112013004714A patent/BR112013004714A2/pt not_active IP Right Cessation
- 2011-08-31 EP EP11755492.3A patent/EP2611436A1/en not_active Withdrawn
-
2015
- 2015-11-30 US US14/954,115 patent/US20160199350A1/en not_active Abandoned
-
2016
- 2016-01-06 JP JP2016001183A patent/JP2016128437A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112013004714A2 (pt) | 2016-05-17 |
| JP2016128437A (ja) | 2016-07-14 |
| JP2013538810A (ja) | 2013-10-17 |
| EP2611436A1 (en) | 2013-07-10 |
| WO2012030886A1 (en) | 2012-03-08 |
| AU2011296047A1 (en) | 2013-03-21 |
| MX2013002503A (es) | 2013-04-29 |
| US20160199350A1 (en) | 2016-07-14 |
| CN103079551A (zh) | 2013-05-01 |
| CA2808908A1 (en) | 2012-03-08 |
| KR20130101519A (ko) | 2013-09-13 |
| CN104399081A (zh) | 2015-03-11 |
| US20130171141A1 (en) | 2013-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2008107871A (ru) | Применение ингибиторов hdac для лечения миеломы | |
| EA200802412A1 (ru) | Терапевтические комбинации для сопровождающихся болью медицинских состояний | |
| TN2009000344A1 (en) | Combinations of therapeutic agents for treating cancer | |
| CY1109363T1 (el) | Υδροξαμικες ενωσεις ως θεραπευτικοι παραγοντες | |
| RU2015107877A (ru) | Способы лечения болезни альцгеймера и фармацевтические композиции | |
| AR045318A1 (es) | Composicion farmaceutica que contiene un inhibidor de histona deacetilasa | |
| EA201490016A1 (ru) | Комбинация панобиностата и руксолитинаба при лечении рака, такого как миелопролиферативное новообразование | |
| EA200800798A1 (ru) | Фармацевтические композиции, предназначенные для лечения нарушений внутреннего уха | |
| CY1107850T1 (el) | Παραγωγα θειαδιαζολυλοπιπεραζiνης mε χρησιμοτητα στην αποτροπη ή στην αγωγη εναντι tου αλγους | |
| JP2013515002A5 (ru) | ||
| EA200801826A1 (ru) | Дейтерированные производные катехоламина и лекарственные средства, содержащие указанные соединения | |
| HRP20100577T1 (hr) | Uporaba agomelatina za dobivanje lijeka s ciljem liječenja općeg poremećaja anksioznosti | |
| JP2019503386A5 (ru) | ||
| PE20080852A1 (es) | Polimorfos de n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida | |
| EA201270266A1 (ru) | Гетероциклические соединения | |
| RU2008129635A (ru) | Ингибиторы ссr9 активности | |
| RU2013114246A (ru) | Комбинация hdac ингибиторов с лекарственными средствами против тромбоцитопении | |
| NO20085028L (no) | Substituerte karboksamider | |
| EA201170784A1 (ru) | Гранулы тамсулозина для фиксированной комбинации | |
| CY1116274T1 (el) | Παραγωγο τριαζολιου για χρηση στη θεραπεια του νευροπαθητικου πονου και της ινομυαλγιας | |
| RU2016119493A (ru) | Пролекарства антагониста NMDA | |
| CY1111430T1 (el) | Χρηση της αγομελατινης για τη ληψη φαρμακων που προοριζονται για τη θεραπεια του συνδρομου smith magenis | |
| RU2008108911A (ru) | Комбинация органических соединений | |
| RS50693B (sr) | Stabilni farmaceutski gel diklofenak natrijuma | |
| CY1111179T1 (el) | Μοναδες ημερησιας δοσολογιας μελατονινης |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20160825 |